Hormonal replacement therapy (HRT) in postmenopause: a reappraisal

Annales d'Endocrinologie

Volumn 68, Issue 4, 2007, Pages 241-250

  Caufriez, A ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Estrogens; HRT (hormone replacement therapy); Menopause; Progesterone; Transdermal

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CHLORMADINONE ACETATE; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; DROSPIRENONE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; HYDROCORTISONE; LEVONORGESTREL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; NOMEGESTROL ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTREL; PHYTOESTROGEN; PROGESTERONE; PROMEGESTONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; THYROXINE; TIBOLONE;

ADJUVANT THERAPY; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DEPRESSION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRY SKIN; FRACTURE; GENETIC SCREENING; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LEG CRAMP; LIBIDO DISORDER; MENOPAUSAL SYNDROME; MENOPAUSE; MONOTHERAPY; NONHUMAN; OSTEOPOROSIS; OVARY CANCER; PERIPHERAL EDEMA; POSTMENOPAUSE; RISK BENEFIT ANALYSIS; SKIN ATROPHY; SLEEP DISORDER; TREATMENT DURATION; UROGENITAL TRACT DISEASE; VASOMOTOR DISORDER;

ANIMALS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; COGNITION; COLORECTAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIAN NEOPLASMS; POSTMENOPAUSE; PROGESTERONE;

EID: 34548416225     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2007.06.015     Document Type: Article

References (107)

1. Tilly J.L. Oocyte apoptosis: prevention strategies, and implications for female aging and the menopause. Ann. Endocrinol. (Paris) 64 (2003) 82-84
2. Brody J.A., Grant M.D., Frateschi L.J., Miller S.C., and Zhang H. Reproductive longevity and increased life expectancy. Age Ageing 29 (2000) 75-78
3. Rosenberg M. Menarcheal age for Norwegian women born 1830-1960. Ann. Hum. Biol. 18 (1991) 207-219
4. Whiteman M.K., Staropoli C.A., Benedict J.C., Borgeest C., and Flaws J.A. Risk factors for hot flashes in midlife women. J. Womens Health (Larchmt) 12 (2003) 459-472
5. Freedman R.R. Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Fertil. Steril. 70 (1998) 332-337
6. Burger H.G., Dudley E.C., Robertson D.M., and Dennerstein L. Hormonal changes in the menopause transition. Recent Prog. Horm. Res. 57 (2002) 257-275
7. Oldenhave A., Jaszmann L.J., Haspels A.A., and Everaerd W.T. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am. J. Obstet. Gynecol. 168 (1993) 772-780
8. Rodstrom K., Bengtsson C., Lissner L., Milsom I., Sundh V., and Bjorkelund C. A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause 9 (2002) 156-161
9. Hickey M., Davis S.R., and Sturdee D.W. Treatment of menopausal symptoms: what shall we do now?. Lancet 366 (2005) 409-421
10. Kannel W.B., Hjortland M.C., McNamara P.M., and Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann. Intern. Med. 85 (1976) 447-452
11. van der Schouw Y.T., van der Graaf Y., Steyerberg E.W., Eijkemans J.C., and Banga J.D. Age at menopause as a risk factor for cardiovascular mortality. Lancet 347 (1996) 714-718
12. Venkov C.D., Rankin A.B., and Vaughan D.E. Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. Circulation 94 (1996) 727-733
13. Kim-Schulze S., McGowan K.A., Hubchak S.C., Cid M.C., Martin M.B., Kleinman H.K., et al. Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation 94 (1996) 1402-1407
14. Alvarez R.J., Gips S.J., Moldovan N., Wilhide C.C., Milliken E.E., Hoang A.T., et al. 17 beta-estradiol inhibits apoptosis of endothelial cells. Biochem. Biophys. Res. Commun. 237 (1997) 372-381
15. Menon D.V., and Vongpatanasin W. Effects of transdermal estrogen replacement therapy on cardiovascular risk factors. Treat. Endocrinol. 5 (2006) 37-51
16. Ho K.K., O'Sullivan A.J., Wolthers T., and Leung K.C. Metabolic effects of oestrogens: impact of the route of administration. Ann. Endocrinol. (Paris) 64 (2003) 170-177
17. Murphy L.J., and Friesen H.G. Differential effects of estrogen and growth hormone on uterine and hepatic insulin-like growth factor I gene expression in the ovariectomized hypophysectomized rat. Endocrinology 122 (1988) 325-332
18. Friend K.E., Hartman M.L., Pezzoli S.S., Clasey J.L., and Thorner M.O. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women: a clinical research center study. J. Clin. Endocrinol. Metab. 81 (1996) 2250-2256
19. Lissett C.A., and Shalet S.M. The impact of dose and route of estrogen administration on the somatotropic axis in normal women. J. Clin. Endocrinol. Metab. 88 (2003) 4668-4672
20. Spencer C.P., Godsland I.F., Cooper A.J., Ross D., Whitehead M.I., and Stevenson J.C. Effects of oral and transdermal 17 beta-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. Metabolism 49 (2000) 742-747
21. Rizza R.A., Mandarino L.J., and Gerich J.E. Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am. J. Physiol. 240 (1981) E630-E639
22. Ho K.K., Jenkins A.B., Furler S.M., Borkman M., and Chisholm D.J. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin. Endocrinol. (Oxf.) 36 (1992) 271-279
23. Jorgensen J.O., Pedersen S.A., Thuesen L., Jorgensen J., Ingemann-Hansen T., Skakkebaek N.E., et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1 (1989) 1221-1225
24. Moller N., Jorgensen J.O., Alberti K.G., Flyvbjerg A., and Schmitz O. Short-term effects of growth hormone on fuel oxidation and regional substrate metabolism in normal man. J. Clin. Endocrinol. Metab. 70 (1990) 1179-1186
25. Salomon F., Cuneo R.C., Hesp R., and Sonksen P.H. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N. Engl. J. Med. 321 (1989) 1797-1803
26. O'Sullivan A.J., Crampton L.J., Freund J., and Ho K.K. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J. Clin. Invest. 102 (1998) 1035-1040
27. Ho K.K., and Weissberger A.J. Impact of short-term estrogen administration on growth hormone secretion and action: distinct route-dependent effects on connective and bone tissue metabolism. J. Bone Miner. Res. 7 (1992) 821-827
28. Godsland I.F. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil. Steril. 75 (2001) 898-915
29. Moorjani S., Dupont A., Labrie F., De Lignieres B., Cusan L., Dupont P., et al. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J. Clin. Endocrinol. Metab. 73 (1991) 373-379
30. De Lignieres B., Basdevant A., Thomas G., Thalabard J.C., Mercier-Bodard C., Conard J., et al. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. J. Clin. Endocrinol. Metab. 62 (1986) 536-541
31. Wakatsuki A., Okatani Y., Ikenoue N., and Fukaya T. Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 106 (2002) 1771-1776
32. Adams M.R., Kaplan J.R., Manuck S.B., Koritnik D.R., Parks J.S., Wolfe M.S., et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 10 (1990) 1051-1057
33. Chen S.J., Li H., Durand J., Oparil S., and Chen Y.F. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 93 (1996) 577-584
34. Sullivan Jr. T.R., Karas R.H., Aronovitz M., Faller G.T., Ziar J.P., Smith J.J., et al. Estrogen inhibits the response-to-injury in a mouse carotid artery model. J. Clin. Invest. 96 (1995) 2482-2488
35. Mikkola T.S., and Clarkson T.B. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc. Res. 53 (2002) 605-619
36. Booth E.A., and Lucchesi B.R. Medroxyprogesterone Acetate Prevents the Cardioprotective and Antiinflammatory Effects of 17 {beta}-estradiol in an in vivo Model of Myocardial Ischemia-Reperfusion. Am. J. Physiol. Heart Circ. Physiol. (2007)
37. Krasinski K., Spyridopoulos I., Asahara T., van der Zee R., Isner J.M., and Losordo D.W. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 95 (1997) 1768-1772
38. Scarabin P.Y., Alhenc-Gelas M., Plu-Bureau G., Taisne P., Agher R., and Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 3071-3078
39. Vehkavaara S., Silveira A., Hakala-Ala-Pietila T., Virkamaki A., Hovatta O., Hamsten A., et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb. Haemost. 85 (2001) 619-625
40. Conard J., Samama M., Basdevant A., Guy-Grand B., and de Lignieres B. Differential AT III-response to oral and parenteral administration of 17 beta-estradiol. Thromb. Haemost. 49 (1983) 252
41. Scarabin P.Y., Plu-Bureau G., Bara L., Bonithon-Kopp C., Guize L., and Samama M.M. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb. Haemost. 70 (1993) 584-587
42. Oger E., Alhenc-Gelas M., Lacut K., Blouch M.T., Roudaut N., Kerlan V., et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1671-1676
43. Modena M.G., Bursi F., Fantini G., Cagnacci A., Carbonieri A., Fortuna A., et al. Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen. Am. J. Med. 113 (2002) 331-334
44. Blumenfeld Z., Boulman N., Leiba R., Siegler E., Shachar S., Linn R., et al. High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol. Scand. J. Clin. Lab. Invest. 67 (2007) 257-263
45. Decensi A., Omodei U., Robertson C., Bonanni B., Guerrieri-Gonzaga A., Ramazzotto F., et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 106 (2002) 1224-1228
46. Malet C., Spritzer P., Guillaumin D., and Kuttenn F. Progesterone effect on cell growth, ultrastructural aspect and estradiol receptors of normal human breast epithelial (HBE) cells in culture. J. Steroid Biochem. Mol. Biol. 73 (2000) 171-181
47. Modena M.G., Sismondi P., Mueck A.O., Kuttenn F., de Lignieres B., Verhaeghe J., et al. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas 52 (2005) 1-10
48. O'Brien S.N., Anandjiwala J., and Price T.M. Differences in the estrogen content of breast adipose tissue in women by menopausal status and hormone use. Obstet. Gynecol. 90 (1997) 244-248
49. Gunnarsson C., Olsson B.M., and Stal O. Abnormal expression of 17 beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Res. 61 (2001) 8448-8451
50. Mueck A.O., Seeger H., and Lippert T.H. Estradiol metabolism and malignant disease. Maturitas 43 (2002) 1-10
51. Mueck A.O., and Seeger H. Smoking, estradiol metabolism and hormone replacement therapy. Arzneimittelforschung 53 (2003) 1-11
52. Danforth K.N., Tworoger S.S., Hecht J.L., Rosner B.A., Colditz G.A., and Hankinson S.E. A prospective study of postmenopausal hormone use and ovarian cancer risk. Br. J. Cancer 96 (2007) 151-156
53. Lacreuse A. Effects of ovarian hormones on cognitive function in nonhuman primates. Neuroscience 138 (2006) 859-867
54. Sherwin B.B. Estrogen and cognitive functioning in women. Endocr. Rev. 24 (2003) 133-151
55. Sherwin B.B. Estrogen and cognitive aging in women. Neuroscience 138 (2006) 1021-1026
56. Arias-Loza P.A., Hu K., Schafer A., Bauersachs J., Quaschning T., Galle J., et al. Medroxyprogesterone acetate but not drospirenone ablates the protective function of 17 beta-estradiol in aldosterone salt-treated rats. Hypertension 48 (2006) 994-1001
57. Winneker R.C., and Parsons J.A. Glucocorticoid-like actions of medroxyprogesterone acetate upon MtTW15 rat mammosomatotropic pituitary tumors. Endocrinology 109 (1981) 99-105
58. Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging 21 (2004) 865-883
59. Chataigneau T., Zerr M., Chataigneau M., Hudlett F., Hirn C., Pernot F., et al. Chronic treatment with progesterone but not medroxyprogesterone acetate restores the endothelial control of vascular tone in the mesenteric artery of ovariectomized rats. Menopause 11 (2004) 255-263
60. Jeanes H.L., Wanikiat P., Sharif I., and Gray G.A. Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia-reperfusion injury. Menopause 13 (2006) 80-86
61. Muhn P., Fuhrmann U., Fritzemeier K.H., Krattenmacher R., and Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann. N. Y. Acad. Sci. 761 (1995) 311-335
62. Fuhrmann U., Krattenmacher R., Slater E.P., and Fritzemeier K.H. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 54 (1996) 243-251
63. Elger W., Beier S., Pollow K., Garfield R., Shi S.Q., and Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids 68 (2003) 891-905
64. Lydon J.P., Ge G., Kittrell F.S., Medina D., and O'Malley B.W. Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function. Cancer Res. 59 (1999) 4276-4284
65. Soderqvist G., von Schoultz B., Tani E., and Skoog L. Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle. Am. J. Obstet. Gynecol. 168 (1993) 874-879
66. Pollow K., Boquoi E., Baumann J., Schmidt-Gollwitzer M., and Pollow B. Comparison of the in vitro conversion of estradiol-17 beta to estrone of normal and neoplastic human breast tissue. Mol. Cell. Endocrinol. 6 (1977) 333-348
67. Fournier S., Kuttenn F., de Cicco F., Baudot N., Malet C., and Mauvais-Jarvis P. Estradiol 17 beta-hydroxysteroid dehydrogenase activity in human breast fibroadenomas. J. Clin. Endocrinol. Metab. 55 (1982) 428-433
68. Foidart J.M., Colin C., Denoo X., Desreux J., Beliard A., Fournier S., et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil. Steril. 69 (1998) 963-969
69. Formby B., and Wiley T.S. Bcl-2, survivin and variant CD44 v7-v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis. Mol. Cell. Biochem. 202 (1999) 53-61
70. Wood C.E., Register T.C., Lees C.J., Chen H., Kimrey S., and Cline J.M. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res. Treat. 101 (2007) 125-134
71. Coldham N.G., and James V.H. A possible mechanism for increased breast cell proliferation by progestins through increased reductive 17 beta-hydroxysteroid dehydrogenase activity. Int. J. Cancer 45 (1990) 174-178
72. Hofseth L.J., Raafat A.M., Osuch J.R., Pathak D.R., Slomski C.A., and Haslam S.Z. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J. Clin. Endocrinol. Metab. 84 (1999) 4559-4565
73. Valdivia I., Campodonico I., Tapia A., Capetillo M., Espinoza A., and Lavin P. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil. Steril. 81 (2004) 617-623
74. Prior J.C. Progesterone as a bone-trophic hormone. Endocr. Rev. 11 (1990) 386-398
75. Schumacher M., Guennoun R., Ghoumari A., Massaad C., Robert F., El-Etr M., et al. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. Endocr. Rev. 28 (2007) 387-439
76. Mueck A.O., and Seeger H. Biochemical markers surrogating on vascular effects of sex steroid hormones. Gynecol. Endocrinol. 22 (2006) 163-173
77. Dubey R.K., Gillespie D.G., Grogli M., Kloosterboer H.J., and Imthurn B. Tibolone and its metabolites induce antimitogenesis in human coronary artery smooth muscle cells: role of estrogen, progesterone, and androgen receptors. J. Clin. Endocrinol. Metab. 89 (2004) 852-859
78. Campisi R., Camilletti J., Mele A., Erriest J., Pedroni P., and Guiglioni A. Tibolone improves myocardial perfusion in postmenopausal women with ischemic heart disease: an open-label exploratory pilot study. J. Am. Coll. Cardiol. 47 (2006) 559-564
79. Vanhoecke B.W., Bracke M.E., Kloosterboer H.J., and Depypere H.T. Tibolone and its metabolites inhibit invasion of human mammary carcinoma cells in vitro. Maturitas 54 (2006) 229-237
80. Desreux J., Kloosterboer H., Noel A., Frankenne F., Lemaire M., Putman M., et al. Effects of tibolone on sulfatase pathway of estrogens metabolism and on growth of MCF-7 human breast tumors implanted in ovariectomized nude mice. Gynecol. Obstet. Invest. 63 (2007) 31-38
81. Rice S., and Whitehead S.A. Phytoestrogens and breast cancer - promoters or protectors?. Endocr. Relat. Cancer 13 (2006) 995-1015
82. Kurzer M.S. Phytoestrogen supplement use by women. J. Nutr. 133 (2003) 1983S-1986S
83. Geller S.E., and Studee L. Botanical and dietary supplements for menopausal symptoms: what works, what does not. J. Womens Health (Larchmt) 14 (2005) 634-649
84. Delmas P., and Chapurlat R.D. Osteoporosis. In: DeGroot JLJ L.J. (Ed). Endocrinology. Vol 2 (2006), Elsevier Saunders, Philadelphia, PA 1751-1769
85. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337 (1997) 1641-1647
86. Barrett-Connor E., Mosca L., Collins P., Geiger M.J., Grady D., Kornitzer M., et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 355 (2006) 125-137
87. Hu F.B., and Grodstein F. Postmenopausal hormone therapy and the risk of cardiovascular disease: the epidemiologic evidence. Am. J. Cardiol. 90 (2002) 26F-29F
88. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
89. Wassertheil-Smoller S., Hendrix S.L., Limacher M., Heiss G., Kooperberg C., Baird A., et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 289 (2003) 2673-2684
90. Pradhan A.D., Manson J.E., Rossouw J.E., Siscovick D.S., Mouton C.P., Rifai N., et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 288 (2002) 980-987
91. Manson J.E., Hsia J., Johnson K.C., Rossouw J.E., Assaf A.R., Lasser N.L., et al. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 349 (2003) 523-534
92. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280 (1998) 605-613
93. Grodstein F., Manson J.E., and Stampfer M.J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J. Womens Health (Larchmt) 15 (2006) 35-44
94. Anderson G.L., Limacher M., Assaf A.R., Bassford T., Beresford S.A., Black H., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
95. Hsia J., Langer R.D., Manson J.E., Kuller L., Johnson K.C., Hendrix S.L., et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch. Intern. Med. 166 (2006) 357-365
96. Viscoli C.M., Brass L.M., Kernan W.N., Sarrel P.M., Suissa S., and Horwitz R.I. A clinical trial of estrogen-replacement therapy after ischemic stroke. N. Engl. J. Med. 345 (2001) 1243-1249
97. Canonico M., Oger E., Plu-Bureau G., Conard J., Meyer G., Levesque H., et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115 (2007) 840-845
98. Rexrode K.M., and Manson J.E. Are some types of hormone therapy safer than others? Lessons from the Estrogen and Thromboembolism Risk study. Circulation 115 (2007) 820-822
99. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350 (1997) 1047-1059
100. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
101. Fournier A., Berrino F., and Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res. Treat. (2007)
102. Beral V., Bull D., Green J., and Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369 (2007) 1703-1710
103. Beral V., Bull D., and Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365 (2005) 1543-1551
104. Rapp S.R., Espeland M.A., Shumaker S.A., Henderson V.W., Brunner R.L., Manson J.E., et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289 (2003) 2663-2672
105. Shumaker S.A., Legault C., Rapp S.R., Thal L., Wallace R.B., Ockene J.K., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289 (2003) 2651-2662
106. Afssaps. Le traitement hormonal de la ménopause (THM). Agence française de sécurité sanitaire des produits de santé (2006)
107. Herrington D.M., Howard T.D., Hawkins G.A., Reboussin D.M., Xu J., Zheng S.L., et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N. Engl. J. Med. 346 (2002) 967-974